PR Newswire | Mar 15, 2021 08:01AM EDT

03/15 07:00 CDT

Enveric Biosciences to Participate in Upcoming Investor Conferences in March NAPLES, Fla., March 15, 2021

NAPLES, Fla., March 15, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will participate in two upcoming investor conferences in March:

* M Vest and Maxim Group Inaugural Emerging Growth Conference to be held virtually on Thursday, March 18, 2021. To attend the conference, register here * Benzinga's Biotech Small Cap Conference to be held virtually on Thursday, March 25, 2021. Mr. Johnson will present at 12:30 p.m. ET. In addition to the corporate presentation, Mr. Johnson will participate on the panel The Natural Solutions: Cannabis & Cannabinoids at 11:40 a.m. ET. To attend the conference, register here.

For more information regarding the conference, or to schedule a one-on-one meeting with Enveric's management team, please contact KCSA Strategic Communications at EnvericBio@kcsa.com or your Maxim Group and Benzinga representatives directly.

About Enveric BiosciencesEnveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.

Investor ContactsValter Pinto / Allison SossKCSA Strategic Communications212.896.1254 / 212.896.1267valter@kcsa.com / asoss@kcsa.com

Media ContactsCaitlin Kasunich / Raquel ConaKCSA Strategic Communications212.896.1241 / 516.779.2630ckasunich@kcsa.com / rcona@kcsa.com

View original content: http://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-march-301246977.html

SOURCE Enveric Biosciences